Conduit Pharmaceuticals (CDT) entered into a strategic services agreement with formulation development CDMO Agility Life Sciences to develop ...

X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare primary immunodeficiency, has been validated for review ...

Years of scouring the bush and breeding work at The University of Queensland have resulted in new varieties of a native Australian plant valuable to the global pharmaceutical industry ...

The groundbreaking technology delivering live beneficial bacteria to the skin is complementary to Young's line of medically formulated products," according to John Kulesza, Young Pharmaceuticals ...

Yunnan Baiyao Group Co. Ltd. A 0.55% ¥107B Tasly Pharmaceutical Group Co. Ltd. A 1.09% ¥21.97B Jiangsu Hengrui Medicine Co. Ltd. A-0.62% ¥293.66B Zhejiang Hisun Pharmaceutical Co. Ltd. A 0.36% ...

SAN RAFAEL, Calif., Jan. 13, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in PTPN2. A new research paper was published in Aging (listed by MEDLINE ...

“My Economy” tells the story of the new economic normal through the eyes of people trying to make it, because we know the only numbers that really matter are the ones in your economy.

(Image Credits: Pixabay) Amid the growing burden of non-communicable diseases and ageing population, the pharmaceutical sector has thrived tremendously over the recent years. Industry leaders ...

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals ...

CHARLOTTESVILLE, Va. and SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating cardiometabolic diseases driven ...

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...